Aptinyx Inc.

0.6000-0.0899-13.03%Vol 358.60K1Y Perf -71.73%
Aug 11th, 2022 16:00 DELAYED
BID0.5801 ASK0.6476
Open0.6850 Previous Close0.6899
Pre-Market- After-Market0.63
 - -  0.03 5.00%
Target Price
4.67 
Analyst Rating
Strong Buy 1.29
Potential %
678.33 
Finscreener Ranking
★★★+     52.25
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★     51.97
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★     46.25
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
7.06 
Earnings Rating
Strong Buy
Market Cap40.63M 
Earnings Date
4th Aug 2022
Alpha-0.06 Standard Deviation0.21
Beta1.28 

Today's Price Range

0.59700.6900

52W Range

0.36003.76

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Neutral
Performance
1 Week
16.55%
1 Month
-9.49%
3 Months
0.00%
6 Months
-82.14%
1 Year
-71.73%
3 Years
-83.47%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APTX0.6000-0.0899-13.03
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-7 453.40
-7 400.80
-1 884.40
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-43.34
-34.38
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.29-0.2610.34
Q01 2022-0.31-0.296.45
Q04 2021-0.35-0.2917.14
Q03 2021-0.31-0.310.00
Q02 2021-0.25-0.29-16.00
Q01 2021-0.21-0.22-4.76
Q04 2020-0.24-0.2016.67
Q03 2020-0.30-0.2420.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.293.33Positive
9/2022 QR-0.2212.00Positive
12/2022 FY-0.9910.00Positive
12/2023 FY-0.7510.71Positive
Next Report Date-
Estimated EPS Next Report-0.29
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume358.60K
Shares Outstanding67.72K
Shares Float51.38M
Trades Count607
Dollar Volume235.17K
Avg. Volume297.95K
Avg. Weekly Volume394.23K
Avg. Monthly Volume186.53K
Avg. Quarterly Volume313.08K

Aptinyx Inc. (NASDAQ: APTX) stock closed at 0.6 per share at the end of the most recent trading day (a -13.03% change compared to the prior day closing price) with a volume of 358.60K shares and market capitalization of 40.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Aptinyx Inc. CEO is Norbert G. Riedel.

The one-year performance of Aptinyx Inc. stock is -71.73%, while year-to-date (YTD) performance is -77.53%. APTX stock has a five-year performance of %. Its 52-week range is between 0.36 and 3.7599, which gives APTX stock a 52-week price range ratio of 7.06%

Aptinyx Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.60, a price-to-sale (PS) ratio of 166.58, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -62.02%, a ROC of -58.53% and a ROE of -71.09%. The company’s profit margin is -%, its EBITDA margin is -7 400.80%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aptinyx Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. Aptinyx Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aptinyx Inc. is Strong Buy (1.29), with a target price of $4.67, which is +678.33% compared to the current price. The earnings rating for Aptinyx Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptinyx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptinyx Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.33, ATR14 : 0.08, CCI20 : 30.97, Chaikin Money Flow : -0.38, MACD : -0.01, Money Flow Index : 50.85, ROC : 0.00, RSI : 43.27, STOCH (14,3) : 60.53, STOCH RSI : 0.76, UO : 42.56, Williams %R : -39.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptinyx Inc. in the last 12-months were: Ashish Khanna (Buy at a value of $101 700), Joan W. Miller (Buy at a value of $50 091), Norbert G. Riedel (Buy at a value of $223 000), Robert J. Hombach (Buy at a value of $192 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (85.71 %)
6 (85.71 %)
6 (85.71 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.29
Strong Buy
1.29
Strong Buy
1.29

Aptinyx Inc.

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.

CEO: Norbert G. Riedel

Telephone: +1 847 871-0377

Address: 909 Davis Street, Evanston 60201, IL, US

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

73%27%

Bearish Bullish

63%37%

Bearish Bullish

66%34%

TipRanks News for APTX

Mon, 16 May 2022 12:35 GMT Analysts Are Bullish on Top Healthcare Stocks: Aptinyx (APTX), Actinium Pharmaceuticals (ATNM)

- TipRanks. All rights reserved.

Thu, 24 Mar 2022 14:59 GMT Aptinyx (APTX) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

Thu, 24 Mar 2022 10:25 GMT Aptinyx (APTX) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits